STUDIES OF FIBRIN DEPOSITION IN CANCER
癌症中纤维蛋白沉积的研究
基本信息
- 批准号:3165770
- 负责人:
- 金额:$ 15.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-07-01 至 1992-06-30
- 项目状态:已结题
- 来源:
- 关键词:acute leukemia anticoagulants chemical structure function complementary DNA cytotoxicity disease /disorder model fibrin fibrinolysis human subject human therapy evaluation immune complex immunoregulation laboratory mouse macrophage membrane activity metastasis monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer immunology neoplasm /cancer invasiveness neoplastic cell radioimmunoassay tissue /cell culture vascular endothelium warfarin
项目摘要
Local and systemic activation of blood coagulation appears to be
a common and an important host response to growing tumors. The
pathogenesis of this process and the importance of the resultant
fibrin deposition to tumor growth remains uncertain. Tumor cells,
tumor-associated macrophages and tumor-associated endothelial cells
contain proteins with potent procoagulant activities (PCAs) and
fibrin deposition has been observed histologically on the surface
of both tumor cells and stromal elements within tumors in situ.
It is the objective of this project to examine this association in
more detail and, using specific probes, to define the importance
of the 2 main types of PCAs in the pathogenesis of fibrin
deposition in human cancer.
Utilizing specific monoclonal antibodies (mAbs) and cDNA probes
specific for the PCAs, cell surface antigens and immunoregulatory
molecules, we will examine the interactions between the 2 principal
tumor-associated PCAs, cancer procoagulant (CP) and tissue factor
(TF), inflammatory cell and vascular cell infiltration and fibrin
deposition in human tumors. We will characterize the PCAs from
homogeneous cell populations isolated from primary and metastatic
tumors in these models, utilizing traditional biochemical methods
and specific immunologic and functional probes. The long-term
goals for this research are to: 1) provide a better understanding
of the mechanism(s) for fibrin deposition in cancer; 2) develop
strategies for the specific inhibition of cell mediated fibrin
deposition; 3) demonstrate inhibition of metastasis formation by
inhibiting cell-mediated clotting.
局部和全身凝血系统的激活似乎是
一种常见且重要的宿主对不断生长的肿瘤的反应。这个
这一过程的发病机制以及由此产生的重要性
纤维蛋白沉积对肿瘤生长的影响仍不确定。肿瘤细胞,
肿瘤相关巨噬细胞和肿瘤相关内皮细胞
含有具有强大促凝血活性的蛋白质(PCA)和
组织学观察到表面有纤维蛋白沉积。
原位肿瘤内肿瘤细胞和间质成分的表达。
本项目的目标是在以下方面检查这种关联
更详细,并使用特定的探测器来定义重要性
纤维蛋白致病机制中的两种主要PCA类型
在人类癌症中沉积。
利用特异性单抗(MAbs)和cDNAs探针
PCAs、细胞表面抗原和免疫调节的特异性
分子,我们将研究两个主要分子之间的相互作用
肿瘤相关蛋白、促癌物质(CP)和组织因子
(Tf)、炎性细胞和血管细胞浸润及纤维蛋白
在人类肿瘤中的沉积。我们将从以下几个方面描述PCA
从原发灶和转移灶分离的均一细胞群
这些模型中的肿瘤,利用传统的生物化学方法
以及特定的免疫和功能探针。长期的
这项研究的目标是:1)更好地了解
研究癌症中纤维蛋白沉积的机制(S);2)发展
细胞介导的纤维蛋白的特异性抑制策略
沉积;3)表现出抑制转移形成的作用
抑制细胞介导的凝血。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FREDERICK R. RICKLES其他文献
FREDERICK R. RICKLES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FREDERICK R. RICKLES', 18)}}的其他基金
FASEB MINORITY SCIENTIST DEVELOPMENT PROGRAM
FASEB 少数族裔科学家发展计划
- 批准号:
6513659 - 财政年份:1996
- 资助金额:
$ 15.43万 - 项目类别:
FASEB MINORITY SCIENTIST DEVELOPMENT PROGRAM
FASEB 少数族裔科学家发展计划
- 批准号:
6941201 - 财政年份:1996
- 资助金额:
$ 15.43万 - 项目类别:
FASEB MINORITY SCIENTIST DEVELOPMENT PROGRAM
FASEB 少数族裔科学家发展计划
- 批准号:
6794158 - 财政年份:1996
- 资助金额:
$ 15.43万 - 项目类别:
FASEB MINORITY SCIENTIST DEVELOPMENT PROGRAM
FASEB 少数族裔科学家发展计划
- 批准号:
6657452 - 财政年份:1996
- 资助金额:
$ 15.43万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 15.43万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 15.43万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 15.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 15.43万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 15.43万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 15.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 15.43万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 15.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 15.43万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 15.43万 - 项目类别:
Studentship Programs














{{item.name}}会员




